Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 02:14 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
PREVENTion With Sglt-2 Inhibition of Acute Kidney Injury in Intensive Care
NCT05468203 · The George Institute · PHASE3 · terminated · last registry update 2026-03-30 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The vanguard phase is complete. Further phases did not proceed due to funding constraints. A revised methodology is planned, requiring a new protocol and approvals.” | – | Registry record, The George Institute |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against SLC5A2 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-11-06Results posted on the registry: University of Virginia, Dapagliflozin 10mg Tab + Placebo (NCT05762952)
- 2026-10-30Results posted on the registry: University of Utah, Empagliflozin (NCT05614115)
- 2026-10-16Results posted on the registry: Eli Lilly and Company, Orforglipron + Dapagliflozin (NCT06192108)
- 2026-09-25Results posted on the registry: AstraZeneca, Part A: Placebo (matching zibotentan capsule & matching dapagliflozin tablet) + Part A: zibotentan (dose B) + dapagliflozin (NCT05516498)
- 2026-09-25Also stopped (terminated): AstraZeneca, Part A: Placebo (matching zibotentan capsule & matching dapagliflozin tablet) + Part A: zibotentan (dose B) + dapagliflozin (NCT05516498)
- 2026-09-22Results posted on the registry: Cantonal Hospital Graubuenden, Empagliflozin + Placebo (NCT06435858)
- 2026-09-21Results posted on the registry: University of Minnesota, Empagliflozin (NCT06149793)
- 2026-09-18Phase 3 first posted: Martin Blomberg Jensen, empagliflozin (Jardiance) 25 mg + Losartan 100 mg (NCT07828002)
- 2026-09-11Phase 3 first posted: Tanta University, Empagliflozin (EMPA) + Metformin (NCT07815808)
- 2026-09-09Results posted on the registry: Inventiva Pharma, Lanifibranor + Placebo (NCT05232071)
- 2026-09-09Phase 3 first posted: Tanta University, Metformin + Dapagliflozin (10mg Tab) (NCT07810998)
- 2026-07-13Results posted on the registry: Bayer, Finerenone (BAY94-8862 ) 10 mg + Empagliflozin (NCT05254002)
- 2026-07-06Phase 3 first posted: Beni-Suef University, Dapagliflozin (NCT07684326)
- 2026-06-30Also stopped (terminated): Washington University School of Medicine, Dapagliflozin (NCT04887935)
- 2026-06-26Results posted on the registry: AstraZeneca, Balcinrenone/dapagliflozin 15 mg/10 mg and matching placebo for dapagliflozin 10 mg + Balcinrenone/dapagliflozin 40 mg/10 mg and matching placebo for dapagliflozin 10 mg (NCT06350123)
- 2026-06-23Phase 3 first posted: AstraZeneca, Elecoglipron + Dapagliflozin (NCT07662109)
- 2026-06-23Phase 3 first posted: AstraZeneca, Elecoglipron + Placebo (NCT07662135)
- 2026-06-23Phase 3 first posted: AstraZeneca, Elecoglipron + Dapagliflozin (NCT07662044)
- 2026-06-18Also stopped (withdrawn): Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Empagliflozin (NCT05960617)
- 2026-06-16Results posted on the registry: The TIMI Study Group, Dapagliflozin + Placebo (NCT04363697)
- 2026-06-09Phase 3 first posted: Sun Yat-sen University, Group A (triple combination intensive therapy group) + Group B (standard therapy group) (NCT07635953)
- 2026-06-08Results posted on the registry: University Health Network, Toronto, Dapagliflozin 10 MG Oral Tablet + Placebo Matching Dapagliflozin Oral Tablet (NCT04965935)
- 2026-06-04Results posted on the registry: Stanford University, Ertugliflozin (NCT04167761)
- 2026-06-03Phase 3 first posted: AstraZeneca, Balcinrenone/dapagliflozin + Dapagliflozin (NCT07624305)
- 2026-05-20Phase 3 first posted: Chittagong Medical College, Dapagliflozin +Finerenone arm + Dapagliflozin arm (NCT07598864)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision